CTRC Institute for Drug Development, University of Texas (San Antonio, TX) › P2B-122

P2B-122

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Phase II
CTRC Institute for Drug Development, University of Texas (San Antonio, TX) · Dr. Muller
consented 2013-06-12

completed

AEs

Serious

Dropout signal

–

Adverse events

Grade 1 nausea with onset in cycle 6 (2013-10-09); assessed as not related to study drug (unlikely); resolved 2013-10-14.

mild assessed

Grade 3 aspartate aminotransferase increased with onset in cycle 3 (2013-08-11); assessed as not related to study drug (unlikely); resolved 2013-08-21.

severe assessed

Grade 2 vomiting with onset in cycle 3 (2013-08-05); assessed as not related to study drug (not related); resolved 2013-08-08.

moderate assessed

Data queries

No data queries. Open queries would appear here for this patient.